Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alphamab Oncology ( (HK:9966) ) just unveiled an announcement.
Alphamab Oncology has appointed veteran finance executive Wang Fei as its chief financial officer, effective March 16, 2026, tasking him with overseeing capital operations, investment and financing management, and investor relations for the group. Wang brings more than 20 years of financial management and capital markets experience, including senior roles at AstraZeneca, China NT Pharma Group, and 3SBio Inc., bolstering Alphamab’s financial leadership as it navigates growth in the competitive biopharmaceutical sector.
The company also announced the resignation of Chai Bo as vice president of capital markets, effective the same date, citing other work commitments and noting there is no disagreement with the firm or issues requiring shareholder attention. The transition underscores Alphamab’s effort to strengthen its capital markets capabilities and investor communications at a time when access to financing and market confidence are critical for oncology-focused drug developers.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong that focuses on oncology therapies. The group develops and commercializes innovative cancer treatments, targeting both the domestic Chinese market and international opportunities through advanced biologic drug research and partnerships.
Average Trading Volume: 1,440,761
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.71B
For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.